<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03181984</url>
  </required_header>
  <id_info>
    <org_study_id>HMME-S1612</org_study_id>
    <nct_id>NCT03181984</nct_id>
  </id_info>
  <brief_title>Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain</brief_title>
  <official_title>Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to provide safety information of hemoporfin during the post-marketing period as
      required by China Food and Drug Administration (CFDA) regulations in order to identify any
      potential drug related treatment factors in the Chinese population, such as
      unknown/unexpected adverse reactions, the incidence of adverse reactions under the routine
      drug uses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>96 weeks after hemoporfin application</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction rating of the overall treatment by subjects</measure>
    <time_frame>8, 24 and 96 weeks after hemoporfin application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction rating of the overall treatment by investigators</measure>
    <time_frame>8 weeks after hemoporfin application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>8 weeks after hemoporfin application</time_frame>
    <description>proportion of patients achieving at least some improvement (color blanching from the baseline &gt;= 20%)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Port-Wine Stain</condition>
  <arm_group>
    <arm_group_label>Hemoporfin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hemoporfin</intervention_name>
    <description>Hemoporfin mediated photodynamic therapy</description>
    <arm_group_label>Hemoporfin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range: 14 to 65 years-oldï¼›

          -  Clinically diagnosed of Port-wine Stain;

          -  Patients receiving hemoporfin based upon the clinical judgment of the investigator;

          -  Written informed consent signed and agreed to receive periodic follow-up

        Exclusion Criteria:

          -  Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic
             constitution;

          -  Scar diathesis;

          -  Pregnancy or unwilling to adopt reliable contraceptive measures during the month after
             drug application;

          -  Be judged not suitable to participate the study by the investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuejun Zhu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jining Tao</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jining Tao</last_name>
    <phone>+86 21 58953355</phone>
    <email>jntao@d-zj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Hebei Medical College of traditional Chinese Medicine</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Herbei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wuxi People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ke Wang</last_name>
      <phone>+86 10 83573066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>PLA Army General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Dermatology Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2017</study_first_submitted>
  <study_first_submitted_qc>June 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Port-Wine Stain</mesh_term>
    <mesh_term>Hemangioma, Capillary</mesh_term>
    <mesh_term>Vascular Malformations</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

